Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago.

Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlighted performance across its approved product portfolio, development accomplishments, and progress across its differentiated oncology pipeline of innovative ADCs and targeted therapies. “Seagen delivered strong performance in the first quarter, with significant growth of 22 percent for both total revenue and net pr.

Seagen Reports First Quarter 2023 Financial Results

Pfizer

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Seagen will receive $229 in cash for each share of Seagen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consi.

SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago. Data will be presented across Seagen's portfolio of approved medicines and pipeline agents in a range of cancer types and in earlier lines of therapy. “Seagen has worked towards revolutionizing cancer care for 25 years by linking scientific innovation to meaningful im.

Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Seagen Inc. (NASDAQ: SGEN) to Pfizer Inc. for $229.00 in cash per share is fair to Seagen shareholders. Halper Sadeh encourages Seagen shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Seagen and its board of dir.

SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders

Buy Seagen Now For An Attractive M&A Arbitrage Opportunity

Pfizer's cash deal for Seagen benefits shareholders. Seagen's pipeline of antibody-drug conjugates (ADCs) looks promising.

Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives.

Seagen to Report First Quarter 2023 Financial Results on April 27, 2023

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.

Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod

– First treatment option combining an antibody-drug conjugate plus a PD-1 inhibitor in this patient population – TOKYO and BOTHELL, Wash. , April 3, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) accelerated approval in the U.S. as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy.

FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Clay Siegall, the Seagen founder who resigned last year following an arrest and allegations of domestic violence, is jumping back into the biotech world as CEO and president of Morphimmune.

Seagen founder Clay Siegall is back in biotech as CEO of Purdue University spinout

Pfizer has been loading up on acquisitions to help strengthen its growth prospects. Acquiring Seagen is a big move for the company, but Pfizer isn't done with M&A yet.

Why Pfizer Likely Isn't Done With M&A After the Seagen Deal

Brookfield Asset Management

Corning

Dividend contenders are a group of companies that have increased the dividend they pay to shareholders for at least 10 years up to 24 years. There are currently over 360 such companies.

3 Dividend Contenders to Buy Now for Long-Term Gains Later

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?

Seattle-area biotech experts are eying the past with a wary eye in the wake of this week's news that Pfizer plans to acquire Bothell, Wash.

Biotech experts wary of Pfizer cutting Seagen workforce — but history reveals silver lining

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023. The broad range of data being presented at this year's meeting includes research from Seagen's approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs.

Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting

Pfizer has been a stock in search of a catalyst all year long. The drugmaker's $43 billion acquisition of Seagen probably isn't the catalyst shareholders were hoping for.

Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?

Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.

Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up

Seattle Genetics (SGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?

NEW YORK , March 14, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seagen Inc. ("Seagen" or the "Company") (NASDAQ: SGEN) in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE).  Under the terms of the merger agreement, the Company's shareholders will receive $229.00 in cash for each share of Seagen owned.

SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.

NEW YORK , March 14, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Seagen, Inc. (NASDAQ: SGEN), relating to its proposed sale to Pfizer Inc. Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/seagen-inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Seagen, Inc. - SGEN

Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed.

How Pfizer's $43 billion acquisition of Seagen could impact the biotech industry in Seattle

Provention Bio Inc

Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners

NEW YORK , March 13, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Seagen Inc. (NASDAQ: SGEN) and its board of directors concerning the proposed acquisition of the company by Pfizer Inc. (NYSE: PFE). Stockholders will receive $229.00 for each share of Seagen stock that they hold.

News for Seagen Stock (SGEN)